Etcamah can be started before visible progression when ESR1 resistance emerges. The bigger change may be how often breast cancer is tested.
ImpediMed’s new FDA clearance adds sarcopenia risk assessment to the SOZO platform, potentially allowing muscle-loss monitoring alongside existing fluid and body-composition measurements.
Natera’s Signatera gains European IVDR certification across multiple cancers, opening a new phase for personalized MRD testing and clinical adoption.
Discover why Roche and Otsuka-owned Astex are pursuing a $515 million cell-cycle breast cancer programme and what risks remain.
Discover how XEOS AURA 10 could improve breast cancer margin detection while cost, workflow demands and false positives limit wider adoption.
Discover whether IceCure’s 70% ProSense installation growth can turn breast cryoablation into a scalable alternative to surgery.
Find out how Roche’s giredestrant FDA priority review could reshape endocrine therapy in early breast cancer.
Veracyte’s ASCO data could reshape chemotherapy decisions in breast and prostate cancer. Find out why genomic testing is gaining ground.
Find out how SalubrisBio’s JK06 data could reshape 5T4-targeted ADC development in lung and breast cancer.
Hologic’s Breast Cancer Index is changing endocrine therapy decisions. The bigger test is adoption in real-world breast cancer care.